Because its phase 3 trial was conducted only in China, the FDA has told Eli Lilly to go back to the drawing board with its promising investigational checkpoint inhibitor sintilimab for the treatment of nonsmall-cell lung cancer (NSCLC).
Source: Drug Industry Daily